Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction
Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the safety and efficacy of twice-daily oral dosing of 6R-BH4
to improve endothelial function, reduce systolic blood pressure and reduce arterial
stiffness.